These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 38963637)

  • 1. High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia.
    Oya S; Ozawa H; Morishige S; Maehiro Y; Umeda M; Takaki Y; Fukuyama T; Yamasaki Y; Nakamura T; Yamaguchi M; Aoyama K; Mouri F; Nagafuji K
    Int J Hematol; 2024 Jul; ():. PubMed ID: 38963637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
    Döhner H; Weber D; Krzykalla J; Fiedler W; Kühn MWM; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Fransecky L; Koller E; Wulf G; Schleicher J; Ringhoffer M; Greil R; Hertenstein B; Krauter J; Martens UM; Nachbaur D; Samra MA; Machherndl-Spandl S; Basara N; Leis C; Schrade A; Kapp-Schwoerer S; Cocciardi S; Bullinger L; Thol F; Heuser M; Paschka P; Gaidzik VI; Saadati M; Benner A; Schlenk RF; Döhner K; Ganser A;
    Lancet Haematol; 2023 Jul; 10(7):e495-e509. PubMed ID: 37187198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.
    Pilorge S; Rigaudeau S; Rabian F; Sarkozy C; Taksin AL; Farhat H; Merabet F; Ghez S; Raggueneau V; Terré C; Garcia I; Renneville A; Preudhomme C; Castaigne S; Rousselot P
    Am J Hematol; 2014 Apr; 89(4):399-403. PubMed ID: 24375467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
    Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
    Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemtuzumab Ozogamicin in
    Schlenk RF; Paschka P; Krzykalla J; Weber D; Kapp-Schwoerer S; Gaidzik VI; Leis C; Fiedler W; Kindler T; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Horst HA; Koller E; Wulf G; Schleicher J; Bentz M; Greil R; Hertenstein B; Krauter J; Martens U; Nachbaur D; Abu Samra M; Girschikofsky M; Basara N; Benner A; Thol F; Heuser M; Ganser A; Döhner K; Döhner H
    J Clin Oncol; 2020 Feb; 38(6):623-632. PubMed ID: 31851556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
    Tavor S; Rahamim E; Sarid N; Rozovski U; Gibstein L; Aviv F; Kirsner I; Naparstek E
    Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):438-43. PubMed ID: 23017331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial.
    Candoni A; Papayannidis C; Martinelli G; Simeone E; Gottardi M; Iacobucci I; Gherlinzoni F; Visani G; Baccarani M; Fanin R
    Am J Hematol; 2018 May; 93(5):655-663. PubMed ID: 29396857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients.
    Borthakur G; Ravandi F; Patel K; Wang X; Kadia T; DiNardo C; Garcia-Manero G; Pemmaraju N; Jabbour EJ; Takahashi K; Ohanian M; Daver N; Alvarado Y; Brandt M; Pierce S; Kantarjian H
    Am J Hematol; 2022 Nov; 97(11):1427-1434. PubMed ID: 36053747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia.
    Bourne G; Diebold K; Espinoza-Gutarra M; Al-Kadhimi Z; Bachiashvili K; Rangaraju S; Vachhani P; Bhatia R; Jamy O
    Leuk Res; 2024 Apr; 139():107467. PubMed ID: 38460432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With
    Russell NH; Wilhelm-Benartzi C; Othman J; Dillon R; Knapper S; Batten LM; Canham J; Hinson EL; Betteridge S; Overgaard UM; Gilkes A; Potter N; Mehta P; Kottaridis P; Cavenagh J; Hemmaway C; Arnold C; Freeman SD; Dennis M;
    J Clin Oncol; 2024 Apr; 42(10):1158-1168. PubMed ID: 38215358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No Evidence that
    Castaño-Bonilla T; Barragán E; Sargas C; Sanz A; Algarra L; Herrera-Puente P; García-Boyero R; Barrios M; Martinez-Cuadron D; Rodriguez-Veiga R; Boluda B; Gil C; Serrano-López J; Martínez-López J; Sayas-Lloris MJ; Olave MT; Riaza-Grau R; Castillo TB; Larrayoz MJ; Amigo R; Jiménez-Velasco A; Sánchez J; Ayala R; Blas C; Lainez D; Serrano-López J; Sanz MA; Alonso-Domínguez JM; Montesinos P
    Dis Markers; 2022; 2022():3132941. PubMed ID: 36051360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia.
    Borthakur G; Cortes JE; Estey EE; Jabbour E; Faderl S; O'Brien S; Garcia-Manero G; Kadia TM; Wang X; Patel K; Luthra R; Koller C; Brandt M; Ravandi F; Kantarjian H
    Am J Hematol; 2014 Oct; 89(10):964-8. PubMed ID: 24990142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
    Leopold LH; Berger MS; Cheng SC; Cortes-Franco JE; Giles FJ; Estey EH
    Clin Adv Hematol Oncol; 2003 Apr; 1(4):220-5. PubMed ID: 16224410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric
    Pollard JA; Guest E; Alonzo TA; Gerbing RB; Loken MR; Brodersen LE; Kolb EA; Aplenc R; Meshinchi S; Raimondi SC; Hirsch B; Gamis AS
    J Clin Oncol; 2021 Oct; 39(28):3149-3160. PubMed ID: 34048275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
    Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy.
    Mortland L; Alonzo TA; Walter RB; Gerbing RB; Mitra AK; Pollard JA; Loken MR; Hirsch B; Raimondi S; Franklin J; Pounds S; Cao X; Rubnitz JE; Ribeiro RC; Gamis A; Meshinchi S; Lamba JK
    Clin Cancer Res; 2013 Mar; 19(6):1620-7. PubMed ID: 23444229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients.
    Brunnberg U; Mohr M; Noppeney R; Dürk HA; Sauerland MC; Müller-Tidow C; Krug U; Koschmieder S; Kessler T; Mesters RM; Schulz C; Kosch M; Büchner T; Ehninger G; Dührsen U; Serve H; Berdel WE
    Ann Oncol; 2012 Apr; 23(4):990-6. PubMed ID: 21810729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-remission therapy in acute myeloid leukemia: Are we ready for an individualized approach?
    Derman BA; Larson RA
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101102. PubMed ID: 31779969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment.
    Fenwarth L; Fournier E; Cheok M; Boyer T; Gonzales F; Castaigne S; Boissel N; Lambert J; Dombret H; Preudhomme C; Duployez N
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32781546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Benefits and Safety of Gemtuzumab Ozogamicin in Treating Acute Myeloid Leukemia in Various Subgroups: An Updated Systematic Review, Meta-Analysis, and Network Meta-Analysis.
    Xu Q; He S; Yu L
    Front Immunol; 2021; 12():683595. PubMed ID: 34484181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.